Lilly ReoPro sales will be about $40 mil. in second quarter, Centocor exec tells BIO.
Executive Summary
LILLY REOPRO SALES WILL BE ABOUT $40 MIL. IN SECOND QUARTER, CENTOCOR VP-Worldwide Marketing and Sales Don Perryman told the Biotechnology Industry Organization annual conference June 11 in Philadelphia. ReoPro (abciximab), a monoclonal antibody IIb-IIIa antagonist, is marketed by Lilly and manufactured by Centocor. The ReoPro PLA was approved by FDA on Dec. 22, 1994 ("The Pink Sheet" Jan. 2, 1995, p. 16).